Overview

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

Status:
Active, not recruiting

Trial end date:
2021-08-30

Target enrollment:

Participant gender:

Summary

Coronavirus (COVID-19) is a somewhat new and recognized infectious disease that is now spreading to several countries in the world, including Brazil. Hydroxychloroquine and azithromycin may be useful for treating those patients. COALITION I study aims to compared standard of care, hydroxychloroquine plus azithromycin and hydroxychloroquine monotherapy for treatment of hospitalized patients with COVID-19. COALITION I will recruit 630 patients with infection by COVID-19 (210 per arm). Ordinal endpoint of status at 15 days will be the primary endpoint.

Phase:

Phase 3

Details

Lead Sponsor:

Hospital do Coracao

Collaborators:

Brazilian Research In Intensive Care Network
EMS
Hospital Israelita Albert Einstein
Hospital Sirio-Libanes

Treatments:

Azithromycin
Hydroxychloroquine